Magazine: Big biopharma take on the ADC challenge
Antibody‑drug conjugates (ADCs) remain an area of extreme focus in the pharmaceuticals space, with the market projected to hit a…
Antibody‑drug conjugates (ADCs) remain an area of extreme focus in the pharmaceuticals space, with the market projected to hit a…
Every aspect of science and research is based on data, and across the globe, labs are producing more data than…
Ovarian cancer is one of the most challenging malignancies in oncology. Despite advances in diagnosis and treatment, it is still…
The upcoming EpiPen patent expiration on 11 September 2025 sets the stage for a pivotal shift in the epinephrine delivery…
The UK and India’s newly signed £4.8bn ($6.45bn) free trade agreement (FTA) is expected to give rise to new opportunities…
Life sciences venture capital (VC) company Omega Funds has closed its eighth fund, with capital commitments totalling $647m. As with…
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for EURneffy, an adrenaline (epinephrine) nasal spray for…
According to GlobalData analysis, currently marketed and pipeline cell therapy assets in oncology will generate sales of around $25bn by…
Artificial intelligence (AI) should soon be taking a greater role in areas including patient recruitment and in building efficiencies around…
With the US Food and Drug Administration (FDA) shifting its clinical trial regulations in recent years, working closely with regulators…